Jane Street
CLGN icon

Jane Street’s CollPlant Biotechnologies CLGN Stock Holding History

Jane Street’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,265
Closed -$90K – 9233
2022
Q3 		$90K Buy
+13,265
New +$108K ﹤0.01% 8700

Other funds holding CLGN

RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
IMOV
Investment Management of Virginia Richmond, Virginia $526M AUM 3.23% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
BFEC
Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return
SQA
Simon Quick Advisors Morristown, New Jersey $2.19B AUM 17.29% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Jane Street's CLGN Position: Q4 2022 in Review

Jane Street sold out of CollPlant Biotechnologies (CLGN) in Q4 2022, closing a stake of 13,265 shares — an estimated $90K sold.

Jane Street first reported a position in CLGN in Q3 2022 and held it in 1 quarter. The position peaked at $90K in Q3 2022. 18 funds tracked by Wall St. Rank hold CLGN as of Q4 2022.

  • Jane Street reported no remaining CollPlant Biotechnologies position as of Q4 2022 after selling out during the quarter.
  • Jane Street sold 13,265 CollPlant Biotechnologies shares in Q4 2022, an estimated $90K.
  • Jane Street first reported a position in CollPlant Biotechnologies in Q3 2022 and held it in 1 quarter.
  • Jane Street's CollPlant Biotechnologies position peaked at $90K in Q3 2022.
  • 18 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q4 2022.

Based on Jane Street's 13F filing for Q4 2022, filed 15 Feb 2023.